CBT
BMRN icon

Capital Bank & Trust’s BioMarin Pharmaceuticals BMRN Stock Holding History

Capital Bank & Trust’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-11
Closed -$1K – 341
2020
Q1 		$1K Buy
+11
New +$948 ﹤0.01% 655
2019
Q4 		– Sell
-449
Closed -$30K – 721
2019
Q3 		$30K Hold
449
– – ﹤0.01% 477
2019
Q2 		$38K Buy
449
+125
+39% +$10.7K ﹤0.01% 454
2019
Q1 		$29K Sell
324
-216
-40% -$20K ﹤0.01% 443
2018
Q4 		$46K Hold
540
– – ﹤0.01% 428
2018
Q3 		$52K Buy
540
+485
+882% +$48.4K ﹤0.01% 450
2018
Q2 		$5K Buy
+55
New +$4.82K ﹤0.01% 583

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Capital Bank & Trust's BMRN Position: Q2 2020 in Review

Capital Bank & Trust sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2020, closing a stake of 11 shares — an estimated $1K sold.

Capital Bank & Trust first reported a position in BMRN in Q2 2018 and held it in 7 quarters. The position peaked at $52K in Q3 2018. 527 funds tracked by Wall St. Rank hold BMRN as of Q2 2020.

  • Capital Bank & Trust reported no remaining BioMarin Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Capital Bank & Trust sold 11 BioMarin Pharmaceuticals shares in Q2 2020, an estimated $1K.
  • Capital Bank & Trust first reported a position in BioMarin Pharmaceuticals in Q2 2018 and held it in 7 quarters.
  • Capital Bank & Trust's BioMarin Pharmaceuticals position peaked at $52K in Q3 2018.
  • 527 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2020.

Based on Capital Bank & Trust's 13F filing for Q2 2020, filed 14 Aug 2020.